$5.13
5.34% yesterday
Nasdaq, Dec 08, 10:10 pm CET
ISIN
US00289Y1073
Symbol
ABEO

Abeona Therapeutics, Inc. Stock price

$5.13
+0.90 21.28% 1M
-1.41 21.56% 6M
-0.44 7.90% YTD
-0.79 13.34% 1Y
+2.00 63.90% 3Y
-33.12 86.59% 5Y
-88.12 94.50% 10Y
-4,369.87 99.88% 20Y
Nasdaq, Closing price Mon, Dec 08 2025
+0.26 5.34%
ISIN
US00289Y1073
Symbol
ABEO
Industry

Key metrics

Basic
Market capitalization
$278.0m
Enterprise Value
$90.6m
Net debt
positive
Cash
$207.1m
Shares outstanding
52.4m
Valuation (TTM | estimate)
P/E
3.4 | 4.1
P/S
695.0 | 9.9
EV/Sales
226.6 | 3.2
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
40.4%
Return on Equity
-144.8%
ROCE
-39.8%
ROIC
-468.9%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$400.0k | $28.0m
EBITDA
$-81.7m | -
EBIT
$-83.2m | $-67.8m
Net Income
$82.4m | $65.9m
Free Cash Flow
$-82.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-40.5% | -
EBIT
-37.0% | -5.5%
Net Income
215.9% | 203.3%
Free Cash Flow
-62.8%
Margin (TTM | estimate)
Gross
-122.0%
EBITDA
-20,412.5% | -
EBIT
-20,802.3%
Net
20,587.5% | 235.0%
Free Cash Flow
-20,590.0%
More
EPS
$1.5
FCF per Share
$-1.6
Short interest
26.7%
Employees
136
Rev per Employee
$0.0
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.40 0.40
-
100%
- Direct Costs 0.49 0.49
-
123%
-0.49 -0.49
-
-123%
- Selling and Administrative Expenses 54 54
93% 93%
13,483%
- Research and Development Expense 29 29
11% 11%
7,273%
-82 -82
40% 40%
-20,413%
- Depreciation and Amortization 1.56 1.56
40% 40%
390%
EBIT (Operating Income) EBIT -83 -83
37% 37%
-20,802%
Net Profit 82 82
216% 216%
20,588%

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 20 hours ago
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN was administered at Lucile Packard Childr...
Neutral
GlobeNewsWire
8 days ago
CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
27 days ago
Abeona Therapeutics delivered strong 3Q25 results, with a narrowed net loss and $207.5 million in cash supporting a two-year runway. Zevaskyn's commercial launch is delayed to 4Q25 due to FDA assay requirements, but demand and payer coverage remain robust, aided by a new CMS J-code. ABEO's financials improved significantly, with reduced R&D expenses and a strengthened balance sheet, positioning...
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 136
Founded 1974
Website abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today